The H1 23 results exceeded expectations, with a strong showing from all three divisions, which also helped the firm clock a better performance than its peers. Considering the healthy momentum, the management again upgraded the guidance for ‘Generics’. Overall, with the expanding product portfolio and increasing focus on the treatment of chronic diseases, Hikma stands to benefit from the promising long-term growth prospects of generics and biosimilars, which also backs our positive stance on the ....
03 Aug 2023
Strong H1; Generics’ outlook upgraded ‘again’
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong H1; Generics’ outlook upgraded ‘again’
Hikma Pharmaceuticals Plc (HIK:LON) | 1,917 1131 3.2% | Mkt Cap: 4,254m
- Published:
03 Aug 2023 -
Author:
Abhishek Raval -
Pages:
4
The H1 23 results exceeded expectations, with a strong showing from all three divisions, which also helped the firm clock a better performance than its peers. Considering the healthy momentum, the management again upgraded the guidance for ‘Generics’. Overall, with the expanding product portfolio and increasing focus on the treatment of chronic diseases, Hikma stands to benefit from the promising long-term growth prospects of generics and biosimilars, which also backs our positive stance on the ....